CN105338985A - 用于增加瘦素生成的比马前列素 - Google Patents

用于增加瘦素生成的比马前列素 Download PDF

Info

Publication number
CN105338985A
CN105338985A CN201480012846.5A CN201480012846A CN105338985A CN 105338985 A CN105338985 A CN 105338985A CN 201480012846 A CN201480012846 A CN 201480012846A CN 105338985 A CN105338985 A CN 105338985A
Authority
CN
China
Prior art keywords
bimatoprost
administered
treatment
human
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480012846.5A
Other languages
English (en)
Chinese (zh)
Inventor
N·J·波洛索
R·M·伯克
M·E·贾斯特
D·F·伍德沃
T·J·马兹阿斯
S·卡纳莉
G·查尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN105338985A publication Critical patent/CN105338985A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480012846.5A 2013-03-15 2014-03-13 用于增加瘦素生成的比马前列素 Pending CN105338985A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793132P 2013-03-15 2013-03-15
US61/793,132 2013-03-15
PCT/US2014/026110 WO2014143629A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Publications (1)

Publication Number Publication Date
CN105338985A true CN105338985A (zh) 2016-02-17

Family

ID=50442712

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480012846.5A Pending CN105338985A (zh) 2013-03-15 2014-03-13 用于增加瘦素生成的比马前列素

Country Status (11)

Country Link
US (2) US20140275272A1 (https=)
EP (1) EP2968361A1 (https=)
JP (1) JP2016513647A (https=)
KR (1) KR20150129735A (https=)
CN (1) CN105338985A (https=)
AU (1) AU2014228307A1 (https=)
BR (1) BR112015021859A2 (https=)
CA (1) CA2901529A1 (https=)
HK (1) HK1220385A1 (https=)
RU (1) RU2015134772A (https=)
WO (1) WO2014143629A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
WO2012099942A2 (en) * 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
CA2749352A1 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007111806A2 (en) * 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
WO2012099942A2 (en) * 2011-01-19 2012-07-26 Terakine Therapeutics, Inc. Methods and compositions for treating metabolic syndrome

Also Published As

Publication number Publication date
JP2016513647A (ja) 2016-05-16
BR112015021859A2 (pt) 2017-07-18
WO2014143629A1 (en) 2014-09-18
HK1220385A1 (zh) 2017-05-05
RU2015134772A3 (https=) 2018-03-21
US20160310505A1 (en) 2016-10-27
CA2901529A1 (en) 2014-09-18
US20140275272A1 (en) 2014-09-18
RU2015134772A (ru) 2017-04-21
AU2014228307A1 (en) 2015-09-10
KR20150129735A (ko) 2015-11-20
EP2968361A1 (en) 2016-01-20

Similar Documents

Publication Publication Date Title
US7682623B2 (en) Pharmaceutical composition for topical application
US8512718B2 (en) Pharmaceutical composition for topical application
JP5118633B2 (ja) 医療用デバイスおよび医薬製剤において有用な粘膜付着性キシログルカン含有製剤
KR101954869B1 (ko) 탈모증 치료제
EP2481747A1 (en) Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
TW201345538A (zh) 牛樟芝用於治療疾病的方法
CA2688766A1 (en) Compositions and methods for treatment of multiple sclerosis
WO2009015561A1 (en) The use of leonurine and compositions thereof
US20210220260A1 (en) Topical injectable composition
JP2006504666A (ja) デヒドロエピアンドロステロン・ステロイド及び抗ムスカリン薬で呼吸器及び肺の疾患を治療するための組成物、配合物及びキット
CN108635511A (zh) 白芍和铁皮石斛在制备治疗高血压药物中的应用方法
CN105338985A (zh) 用于增加瘦素生成的比马前列素
CN112770765B (zh) 用于预防和/或治疗泌尿生殖器粘膜的组合物
CA2433101A1 (en) Method of treatment of a female suffering from androgen insufficiency
WO2011064769A1 (en) Methods and pharmaceutical compositions for the treatment of hot flashes
KR20230041964A (ko) 박테리아 균주를 포함하는 조성물 및 눈 질환과 병변을 치료하기 위한 그 용도
TWI862350B (zh) 治療表皮分解性水疱症的方法
EP3823622A1 (en) Methods and compositions for promoting wound healing in a subject suffering from ectodermal dysplasias
JP5667565B2 (ja) 閉経期、ホルモン変動および関節炎と関連する症状を治療するための組成物および方法
JP5023323B2 (ja) アクアポリン５の発現亢進剤
Fernandes et al. Efficacy of mitomycin C in adjunct with intralesional steroids in the management of oral submucous fibrosis: A case report
Bende et al. Topical Terlipressin (Glypressin®) Gel Reduces Nasal Mucosal Blood Flow but Leaves Ongoing Nose-bleeding Unaffected
KR20240025512A (ko) 건선의 치료 방법
CN117257790A (zh) 芹菜素在制备用于治疗银屑病的药物中的应用
CN118203578A (zh) 奥赛利定在制备预防或治疗围术期低体温的药物中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160217